[Exogenous activated protein C in severe sepsis]

Area of Science:

• Pharmacology and Critical Care Medicine
• Sepsis Pathophysiology and Treatment

Background:

• Severe sepsis is characterized by systemic inflammation and microcirculatory dysfunction, leading to multiple organ failure.
• Activated protein C (APC) exhibits anti-inflammatory, anticoagulant, and profibrinolytic properties.
• These multifaceted effects suggest a potential therapeutic role for APC in sepsis management.

Purpose of the Study:

• To evaluate the efficacy of exogenous activated protein C, specifically drotrecogine alpha (activated), in patients with severe sepsis.
• To assess the impact of drotrecogine alpha (activated) on survival and organ function in sepsis with multiple organ dysfunction and septic shock.

Main Methods:

• A Russian cooperative study was conducted to assess the clinical efficacy of drotrecogine alpha (activated).
• The study included patients diagnosed with sepsis, multiple organ dysfunction, and septic shock.
• Therapy with drotrecogine alpha (activated) was administered, with a focus on the timing of initiation.

Main Results:

• Inclusion of drotrecogine alpha (activated) in therapy for sepsis with multiple organ dysfunction and septic shock resulted in increased estimated survival.
• Optimal outcomes, including the greatest survival benefit, were observed when treatment was initiated within 48 hours of developing multiple organ deficiency.
• Drotrecogine alpha (activated) demonstrated significant improvements in multiple organ microcirculation.

Conclusions:

• Exogenous activated protein C (drotrecogine alpha (activated)) is a valuable therapeutic agent for severe sepsis.
• Early intervention with drotrecogine alpha (activated) within 48 hours of multiple organ deficiency onset is crucial for maximizing survival benefits.
• The anti-inflammatory and pro-hemodynamic effects of drotrecogine alpha (activated) contribute to preventing irreversible organ damage in critical illness.